pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Veltassa
drug
save

patiromer sorbitex calcium

Marketedupdated 3mo ago
by Vifor Pharma Inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying patiromer sorbitex calcium

  • phase4Potassium Correction for RAAS Optimization in Chronic Kidney Diseaserecruitingn=44
  • phase3Patiromer Trial in CKD Stage IIIB to Vterminatedn=2
  • —Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemiacompletedn=147
  • phase4Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Managementterminatedn=115

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 2, 2026
67 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (28)

  • Oct 8, 2033method-of-use (U-1766)US 11123363
  • Oct 8, 2033method-of-use (U-1766)US 11123363
  • Oct 8, 2033method-of-use (U-1766)US 11123363
  • Oct 8, 2033method-of-use (U-1766)US 11123363
  • Oct 8, 2033method-of-use (U-1766)US 9492476
  • Oct 8, 2033method-of-use (U-1766)US 9492476
  • Oct 8, 2033method-of-use (U-1766)US 9492476
  • Oct 8, 2033method-of-use (U-1766)US 9492476
  • Oct 8, 2033method-of-use (U-1766)US 9925212
  • Oct 8, 2033method-of-use (U-1766)US 9925212
  • Oct 8, 2033method-of-use (U-1766)US 9925212
  • Oct 8, 2033method-of-use (U-1766)US 9925212
  • May 29, 2030compositionUS 83378243.8y
  • May 29, 2030compositionUS 83378243.8y
  • May 29, 2030compositionUS 83378243.8y
  • May 29, 2030compositionUS 83378243.8y
  • Jun 20, 2028formulationUS 81478731.9y
  • Jun 20, 2028formulationUS 81478731.9y
  • Jun 20, 2028formulationUS 81478731.9y
  • Jun 20, 2028formulationUS 81478731.9y
  • May 29, 2027formulationUS 8282913306d
  • May 29, 2027formulationUS 8282913306d
  • May 29, 2027formulationUS 8282913306d
  • May 29, 2027formulationUS 8282913306d
  • Mar 14, 2027method-of-use (U-1766)US 8216560230d
  • Mar 14, 2027method-of-use (U-1766)US 8216560230d
  • Mar 14, 2027method-of-use (U-1766)US 8216560230d
  • Mar 14, 2027method-of-use (U-1766)US 8216560230d

FDA exclusivities (4)

  • Oct 2, 2026NPPNew Product (3y)67d
  • Oct 2, 2026NPPNew Product (3y)67d
  • Oct 2, 2026NPPNew Product (3y)67d
  • Oct 2, 2026NSNS67d

News(0)

no news has mentioned this drug yet

brand
Veltassa
generic
patiromer sorbitex calcium
indication
Hyperkalemia
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 54m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?